Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Slade

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Biometrics|February 24, 2025
Potential outcome simulation for efficient head-to-head comparison of adaptive dose-finding designsMichael Sweeting, Daniel Slade, Dan Jackson, et al.
BMC Medical Research Methodology|June 12, 2020
Do we need to adjust for interim analyses in a Bayesian adaptive trial design?Elizabeth G Ryan, Kristian Brock, Simon Gates, et al.
The American Journal of Emergency Medicine|May 24, 2015
Performance of an expedited rhythm control method for recent onset atrial fibrillation in a community hospitalJennifer L White, Michael B Heller, Robert J Kahoud, et al.
American Journal of Pharmaceutical Education|November 1, 2023
A Scoping Review of eProfessionalism in Healthcare Education LiteratureChristine Slade, Karen McCutcheon, Nuala Devlin, et al.
Pediatric Neurosurgery|April 30, 2024
Management of Pediatric Cavum Cysts: A Scoping Review and a Single Institution Case SeriesHabib Emil Rafka, Eric Scot Shaw, Brian Fabian Saway, et al.
BMC Medical Research Methodology|January 13, 2024
Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trialAmit Patel, Kristian Brock, Daniel Slade, et al.
BMJ Open|March 5, 2022
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trialTobias Menne, Daniel Slade, Joshua Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid LeukemiaCharles Craddock, Daniel Slade, Carmela De Santo, et al.
Investigational New Drugs|December 6, 2025
Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 studyYasutoshi Kuboki, Nobuaki Matsubara, Hiromichi Nakajima, et al.
The Lancet. Haematology|December 15, 2021
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trialMhairi Copland, Daniel Slade, Graham McIlroy, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Biometrics|February 24, 2025
Potential outcome simulation for efficient head-to-head comparison of adaptive dose-finding designsMichael Sweeting, Daniel Slade, Dan Jackson, et al.
BMC Medical Research Methodology|June 12, 2020
Do we need to adjust for interim analyses in a Bayesian adaptive trial design?Elizabeth G Ryan, Kristian Brock, Simon Gates, et al.
The American Journal of Emergency Medicine|May 24, 2015
Performance of an expedited rhythm control method for recent onset atrial fibrillation in a community hospitalJennifer L White, Michael B Heller, Robert J Kahoud, et al.
American Journal of Pharmaceutical Education|November 1, 2023
A Scoping Review of eProfessionalism in Healthcare Education LiteratureChristine Slade, Karen McCutcheon, Nuala Devlin, et al.
Pediatric Neurosurgery|April 30, 2024
Management of Pediatric Cavum Cysts: A Scoping Review and a Single Institution Case SeriesHabib Emil Rafka, Eric Scot Shaw, Brian Fabian Saway, et al.
BMC Medical Research Methodology|January 13, 2024
Implementing the time-to-event continual reassessment method in the presence of partial orders in a phase I head and neck cancer trialAmit Patel, Kristian Brock, Daniel Slade, et al.
BMJ Open|March 5, 2022
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trialTobias Menne, Daniel Slade, Joshua Savage, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid LeukemiaCharles Craddock, Daniel Slade, Carmela De Santo, et al.
Investigational New Drugs|December 6, 2025
Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 studyYasutoshi Kuboki, Nobuaki Matsubara, Hiromichi Nakajima, et al.
The Lancet. Haematology|December 15, 2021
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trialMhairi Copland, Daniel Slade, Graham McIlroy, et al.
Pageof 2